T +49 69 29994 1597
Robert Zehbe is an Associate in White & Case's Global Capital Markets practice.
He advises major corporations, investment banks and private equity houses on high-yield bond issuances as well as public and private debt and equity transactions.
Advising the world's second largest merchant producer of methanol on its 50% acquisition of Natgasoline LLC's sole shareholder and related financing arrangements valued at US$630 million.
Advised the global coordinators Deutsche Bank, J.P. Morgan and Citigroup on the € 294 million IPO of the German wind turbine manufacturer Senvion on the Frankfurt Stock Exchange.
Advising a bank syndicate led by Deutsche Bank and J.P. Morgan on the €1.5 billion leveraged buyout of Senvion SE (now Senvion GmbH) by Centerbridge Capital Partners including a secured €125 million multicurrency revolving credit facility, a secured €825 million multicurrency letter-of-guarantee facility, a secured €180 million super senior cash liquidity facility, as well as a secured €400 million high-yield bond, together with an amendment and restatement agreement required to achieve a successful offering of Senvion GmbH's parent company Senvion S.A.
Advised Stabilus on its €159 million fully documented capital increase.
Advised IPO global coordinators Berenberg, Deutsche Bank and Goldman Sachs on the €304 million IPO of Hapag-Lloyd on the Frankfurt Stock Exchange.
Advised Deutsche Bank and UBS on the IPO of Sunrise Communications Group AG on the Swiss Stock Exchange. It was the largest IPO in Switzerland since 2006 and the largest telecom IPO in Europe since 2004.
Advising Methanol Holdings (Trinidad) Limited, the world's second largest Methanol producer, on its US$590 million refinancing consisting of a US$300 revolving credit facility and a US$290 million US-style term loan B.
Advised Bank am Bellevue AG in connection with the rights offering of Orascom Development Holding AG with a total value of CHF 133.8 million.
Advised Credit Suisse AG, RBC Europe Limited and Bank am Bellevue AG on the CHF54.8 million capital increase of Santhera Pharmaceuticals Holding.